Navigation Links
Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
Date:2/25/2009

er is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer. In 2008, an estimated 186,320 new cases were expected to be diagnosed and approximately 28,660 men were expected to die from the disease. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Overexpression of the androgen receptor is believed to contribute to the progression of castration-resistant prostate cancer. MDV3100 is a novel small-molecule androgen receptor antagonist that inhibits androgen receptor function by blocking nuclear translocation of the androgen receptor and DNA binding.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Medivation Presents New Data on Dimebons Novel Mechanism of Action
2. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
3. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
4. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
5. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
6. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
7. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
8. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
9. Medivation Announces Participation in Upcoming Conferences
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Human Albumin Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study on ... The report provides a basic overview of ... structure. The human albumin market analysis is provided for ...
(Date:9/18/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... with Merck Animal Health to market Neogen,s Igenity ® ... Dairy Heifer Program consists of genomic tests that offer ... of replacement dairy heifers. The genomic tests can be ... an excellent tool in the decision-making process for breeding ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 SeqLL ... Sequencing (tSMS™) technology, announced today the closing of ... investment, led by Genomic Diagnostic Technologies, will increase ... diagnostic applications. , Founded in March 2013 by ... Bioinformatics Analyst at Helicos BioSciences, SeqLL has continued ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2
... and Webcast on May 9 at 8:00 a.m. PDT ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... the three months ended March 31, 2008., "This ... significantly advanced both,our partnered and proprietary programs in the ...
... May 8 Telik, Inc. (Nasdaq:,TELK) today reported a ... for,the first quarter ended March 31, 2008, compared with ... for the comparable period in 2007., For the ... were $10.6 million, compared with $18.0 million during the ...
... to ever increasing,cardiac toxicity found in market drugs, Gwathmey ... Cardionomics(TM) services,and the formation of its Cardionomics(TM) Advisory Board ... of drug candidates., Cardiac toxicity has played a ... over the past 30 years. It is estimated that ...
Cached Biology Technology:Halozyme Therapeutics Reports 2008 First Quarter Financial Results 2Halozyme Therapeutics Reports 2008 First Quarter Financial Results 3Halozyme Therapeutics Reports 2008 First Quarter Financial Results 4Halozyme Therapeutics Reports 2008 First Quarter Financial Results 5Halozyme Therapeutics Reports 2008 First Quarter Financial Results 6Halozyme Therapeutics Reports 2008 First Quarter Financial Results 7Halozyme Therapeutics Reports 2008 First Quarter Financial Results 8Halozyme Therapeutics Reports 2008 First Quarter Financial Results 9Telik Announces First Quarter 2008 Financial Results 2Telik Announces First Quarter 2008 Financial Results 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 2Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 3Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates 4
(Date:9/19/2014)... evolve for the sake of fairness per se but ... so say Frans de Waal, PhD, and Sarah Brosnan, ... (IA), which is defined as a negative reaction to ... . , Their conclusion comes after the co-authors ... hypothesis that it is the evolution of forestalling partner ...
(Date:9/19/2014)... -- Nxt-ID, Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" ... m-commerce market, updates the "Wocket in Your Pocket" celebrity ad campaign, ... middleweight weight classes, Vinny Pazienza (PAZ). ... of Thrones actor Ciaran Hinds and Sons ... Katey Sagal have been cast in Bleed for This ...
(Date:9/18/2014)... Wash. - Washington State University researchers have developed a ... to power waste cleanup in rural areas. , ... to an inexpensive and quick way to clean up ... plants while reducing pollution. , Professor Haluk Beyenal ... of Engineering and Architecture discuss the system in the ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Researchers develop unique waste cleanup for rural areas 2
... over face threats on many fronts: pollution, diseases, destructive fishing ... resistant to one potential menace seaweed than previously ... scientists from the United States and Australia. Their study ... individual reefs in all, more than 3,500 examinations of ...
... different species are likely to respond to climate change. ... species and the interactions between species, in the interest ... BioScience , by Eric Post of Pennsylvania State ... be avoided. Their approach, which relies on multi-stage analyses ...
... (June 1, 2009) The International Serious Adverse Events ... designed to discover genetic markers that may predict individuals ... The SAEC is a nonprofit research corporation, launched ... by 10 leading pharmaceutical companies and the Wellcome Trust. ...
Cached Biology News:In the turf war against seaweed, coral reefs more resilient than expected 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 2International Serious Adverse Events Consortium announces initial study results in its global research collaboration to identify genetic markers related to drug induced liver injury 3
... is a new product number, created ... If showing no availability yet, please ... (Z71,487-9) or contact customer service for ... 100 mm, No. of sidearm 4 ...
... a metabolically stable analog of ... uterine stimulant and abortifacient which ... induce labor. It induces luteolysis ... when given as an intramuscular ...
TGase3 (S-20)...
Amodiaquine...
Biology Products: